Filing Flows › TherapeuticsMD (TXMD) › Q2 2026
TherapeuticsMD (TXMD) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 11, 2026
TherapeuticsMD (TXMD) reported revenue of $869K for the second quarter 2026 (Q2 2026), -9% from a year earlier and +20% from the quarter before. Operating margin was -93.9%, net earnings $155K (17.8% of revenue).
TherapeuticsMD, Q2 2026: revenue $869K (-9% year over year), operating margin -93.9%, net earnings $155K, operating cash flow $779K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $869K | +20% | -9% |
| Operating profit | −$816K | — | — |
| Net earnings | $155K | +63% | -72% |
| Operating cash flow | $779K | -17% | +104% |
What changed
Revenue was $869K in Q2 2026, down 9% year over year and up 20% from the previous quarter.
Operating costs exceeded revenue by $816K, an operating margin of -93.9%. Total costs grew 2% against a revenue fall of 9%. The fastest-growing cost line was Other operating costs (+12%). Net earnings were $155K, down 72% year over year. The effective tax rate was 5.5%. Non-operating items added $1.0M, 598% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $779K (up 104% year over year), 503% of net earnings. Non-cash charges added back $95K of depreciation and amortization and $4K of share-based compensation. Working capital and other items added $525K.
Questions
What was TherapeuticsMD's revenue in the second quarter 2026?
TherapeuticsMD (TXMD) reported revenue of $869K for the second quarter 2026 (Q2 2026), -9% from a year earlier and +20% from the quarter before.
Was TherapeuticsMD profitable in the second quarter 2026?
Operating loss was $816K (-93.9% of revenue) and net earnings $155K.
Source: TherapeuticsMD 10-Q on SEC EDGAR.